Like the European Commission, the US FTC requires agreements settling pharmaceutical patent disputes to be lodged with it. Last week it published its
FDA approves the second Enbrel (etanercept) biosimilarno etanercept biosimilar has launched in the United States to date. FDA approves the fourth
The Federal Trade Commission (“FTC” or “Commission”) has added to its growing list of recent enforcement actions against health care companies, all of
We continue to receive questions regarding the future of the 340B Drug Discount Program (“340B Program”) now that its mid-term longevity is no longer
Within the U.S., patient support programs (“PSPs”) have drawn increased regulator scrutiny, consistent with their growing importance in the healthcare
Below is this week’s “Capitol Hill Healthcare Update,” which is posted on Mondays when Congress is in session
Major court decisions in Europe and the US, a boost for Bristol Meyers’ proposed purchase of Celgene, another AbbeVie Humira suit, a CRISPR grant for
Over the past several years, the environment for pharmaceutical patents in Canada has improved significantly. As was widely reported at the time, the
Third-party payor (TPP) claims against pharmaceutical companies are nothing new. The arguments are common - TPP insurers claim financial injury
The answer to the question of course, depends on the commercial value of the product. However, it is also obvious that the commercial value of a
